Table 1.
Representative clinical trials of stem cells or EVs based therapy in CNS diseases.
| Condition | NCT number | Phase | Intervention | Status | Ref. | 
|---|---|---|---|---|---|
| Ischemic stroke | NCT03545607 | Phase III | Single intravenous infusion of multipotent adult progenitor cells | Recruiting | 4 | 
| NCT03384433 | Phase I/II | Intraparenchymal injection of allogenic MSCs derived exosome | Recruiting | N/A | |
| NCT01716481 | Phase III | Single intravenous administration of autologous MSCs | Unknown | 59 | |
| Alzheimer's disease | NCT02054208 | Phase I/II | Repeated intraventricular administrations of MSCs via an ommaya reservoir at a 4-week interval | Completed | 60 | 
| NCT04388982 | Phase I/II | Repeated IN administrations of MSCs-Exos twice a week for 12 weeks | Recruiting | N/A | |
| Parkinson's disease | NCT04506073 | Phase II | Repeated administrated allogeneic MSCs every 3 months for three doses | Recruiting | N/A | 
| Multiple sclerosis | NCT04047628 | Phase III | Repeated intrathecal or intravenous administration of autologous MSCs at six-month interval for 2 doses | Completed | 47 | 
| Spinal cord injury | NCT02302157 | Phase I/II | Single intralesional administration of oligodendrocyte progenitor cells | Completed | N/A | 
| NCT04520373 | Phase II | Single intrathecal administration of autologous MSCs | Recruiting | N/A | |
| Neonatal stroke | NCT03356821 | Phase I/II | Repeated IN administration of allogeneic MSCs twice within the first week of onset | Completed | N/A | 
Resource of the clinical trial is from ClinicalTrials.gov.
MSCs, mesenchymal stem cells; IN, intranasal; MSCs-Exos, mesenchymal stem cell derived exosomes; N/A, not applicable.